10-Q: Coya Therapeutics Reports Q3 2024 Financial Results and Provides Business Update

Coya Therapeutics reported a net loss of $4.0 million for Q3 2024, while advancing its pipeline and securing additional funding.

Summary

• Coya Therapeutics, a clinical-stage biotechnology company, announced its financial results for the third quarter of 2024, reporting a net loss of $4.0 million, compared to a net loss of $3.4 million for the same period in 2023.
• The company's operating expenses totaled $4.5 million for the quarter, with research and development expenses at $2.2 million and general and administrative expenses at $2.2 million.
• For the nine months ended September 30, 2024, Coya reported a net loss of $12.0 million, compared to a net loss of $9.3 million for the same period in 2023.
• Collaboration revenue for the nine months ended September 30, 2024 was $3.6 million, primarily from the DRL Development Agreement.
• The company's cash and cash equivalents stood at $31.1 million as of September 30, 2024, and with the $10.0 million raised in a private placement in October 2024, they expect to fund operations into 2026.
• Coya is focused on developing therapies to enhance the function of regulatory T cells (Tregs) for neurodegenerative, autoimmune, and metabolic diseases.
• The company's lead asset, COYA 302, is a Treg-enhancing biologic being developed for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson's disease (PD), and Alzheimer's disease (AD).
• A Phase 2 study of COYA 302 in ALS is planned, with the IND submission expected in the second quarter of 2025 after addressing FDA feedback.
• A Phase 2 study of LD IL-2 in AD showed promising results, with a clinically meaningful 4.93-point improvement in the ADAS-Cog14 score compared to placebo in the q4wks dosing group.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company has made progress in its clinical programs and secured additional funding, the increased losses and the delay in the Phase 2 study of COYA 302 in ALS are concerning. The positive results from the Phase 2 study of LD IL-2 in AD are encouraging, but the company still faces significant challenges in bringing its products to market.

Positives

• The company has a strong cash position of $31.1 million as of September 30, 2024, which is expected to fund operations into 2026 with the additional $10.0 million raised in October 2024.
• The company has generated $3.6 million in collaboration revenue for the nine months ended September 30, 2024.
• The Phase 2 study of LD IL-2 in AD showed a clinically meaningful 4.93-point improvement in the ADAS-Cog14 score compared to placebo in the q4wks dosing group.
• The company is expanding its pipeline to include FTD, PD, and AD, which could lead to multiple revenue streams.
• The company has a clear plan to submit an IND for COYA 302 in ALS in the second quarter of 2025.

Negatives

• The company reported a net loss of $4.0 million for the third quarter of 2024 and a net loss of $12.0 million for the nine months ended September 30, 2024.
• The company's research and development expenses increased to $9.9 million for the nine months ended September 30, 2024.
• The company's general and administrative expenses increased to $6.7 million for the nine months ended September 30, 2024.
• The company's planned Phase 2 study of COYA 302 in ALS was delayed due to FDA feedback requiring additional non-clinical data.

Risks

• The company is dependent on the successful development and commercialization of its product candidates, which is subject to significant risks and uncertainties.
• The company may not be able to obtain regulatory approval for its product candidates.
• The company may not be able to generate significant revenue from product sales.
• The company may need to raise additional capital to fund its operations, which may not be available on favorable terms or at all.
• The company's planned Phase 2 study of COYA 302 in ALS was delayed due to FDA feedback requiring additional non-clinical data, which could further delay the development of the product.
• The company is subject to competition from similar products and larger companies.

Future Outlook

The company expects its existing cash and cash equivalents, together with the $10.0 million in gross proceeds from the October 2024 Private Placement, to enable it to fund its operating expenses and capital expenditure requirements into 2026. The company plans to submit an IND for COYA 302 in ALS in the second quarter of 2025 and initiate a Phase 2 study in FTD after the ALS IND is approved. The company is also evaluating the results of the double-blind placebo-controlled trial in AD prior to determining its development plan for COYA 302 in AD patients.

Management Comments

• Management is currently evaluating different strategies to obtain the required funding of future operations.
• Management believes that combination biologics using LD IL-2 as a backbone modality could be the best way to treat neurodegenerative conditions.
• Management believes COYA 302 represents the most clinically advanced of what they hope will be a family of combination therapies that all feature LD IL-2.

Industry Context

The company's focus on Treg-enhancing therapies aligns with the growing interest in immunomodulatory approaches for treating neurodegenerative, autoimmune, and metabolic diseases. The positive results from the Phase 2 study of LD IL-2 in AD highlight the potential of this approach in addressing unmet medical needs in these areas. The expansion of the pipeline to include FTD, PD, and AD reflects a broader trend in the industry to target multiple indications with a single therapeutic platform.

Comparison to Industry Standards

• The reported net loss of $4.0 million for Q3 2024 is typical for a clinical-stage biotechnology company, as these companies often incur significant losses during the research and development phase.
• The cash position of $31.1 million, combined with the $10.0 million raised in October 2024, provides a runway into 2026, which is a reasonable timeframe for a company at this stage of development.
• The collaboration revenue of $3.6 million for the nine months ended September 30, 2024, is a positive sign, indicating the company's ability to secure partnerships and generate revenue from its technology.
• The positive results from the Phase 2 study of LD IL-2 in AD, showing a 4.93-point improvement in the ADAS-Cog14 score, are encouraging and compare favorably to other experimental treatments in the field.
• The expansion of the pipeline to include FTD, PD, and AD is a common strategy for biotechnology companies, as it allows them to leverage their technology platform across multiple indications.
• The delay in the Phase 2 study of COYA 302 in ALS due to FDA feedback is not uncommon in the drug development process, and the company's response to address the FDA's concerns is a standard practice.
• Compared to companies like Biogen and Eisai, who have recently launched AD drugs, Coya is still in the early stages of clinical development, but the positive results from the LD IL-2 study suggest potential for future success.
• Compared to companies like Amylyx Pharmaceuticals, who have recently launched an ALS drug, Coya is still in the early stages of clinical development, but the positive results from the LD IL-2 study suggest potential for future success.

Management Changes

Stakeholder Impact

• Shareholders: The company's financial performance and clinical progress will impact shareholder value. The recent capital raises may dilute existing shareholders.
• Employees: The company's growth and development will impact employee opportunities and job security.
• Patients: The company's clinical programs have the potential to provide new treatment options for patients with neurodegenerative, autoimmune, and metabolic diseases.
• Partners: The company's collaborations with DRL and other partners will impact the development and commercialization of its products.

Next Steps

• The company plans to complete the required nonclinical studies and submit the required data necessary to support its IND for COYA 302 in ALS in the second quarter of 2025.
• The company intends to initiate the proposed Phase 2 clinical trial in patients with ALS upon approval of the IND by the FDA.
• The company intends to file an IND for COYA 302 for the treatment of FTD after the IND for the Phase 2 trial of COYA 302 in patients with ALS is approved by the FDA.
• The company is evaluating the recently announced results of the double-blind placebo-controlled trial in AD prior to determining its development plan for COYA 302 in AD patients.
• The company anticipates that clinical data in FTD patients will be reported for a proof-of-concept, investigator-initiated, open-label study conducted at Houston Methodist Hospital in the second half of 2025.

Key Dates

Keywords

Treg, COYA 302, ALS, Alzheimer's Disease, Neurodegenerative Diseases, Biologics, Clinical Trials, Regulatory Approval, Immunomodulatory, Phase 2 Study